---
title: The Venture Capital Paradox
description: venture capital, Series A funding, GTM execution, go-to-market strategy, startup death valley, execution capital, fundless SPV, LP returns
image: https://lp.plusultra.capital/hubfs/Logos/Blu%20Sqr%20Satoshi%20PUC%20stacked%20lrg.png
---

[Skip to content](https://lp.plusultra.capital/insights/the-venture-capital-paradox-why-85-of-startups-die-at-series-a-and-how-execution-capital-fixes-it#main-content)

[![PUCP SL blu](https://lp.plusultra.capital/hs-fs/hubfs/PUCP%20SL%20blu.png?width=900&height=115&name=PUCP%20SL%20blu.png)](https://plusultra.capital)

Open main navigation

Close main navigation

- [Contact Us](mailto:info@plusultra.capital)

[Contact Us](mailto:info@plusultra.capital)

[All posts](https://lp.plusultra.capital/insights/all)

 October 24, 2025

# The Venture Capital Paradox

![Picture of Pablo Grodnitzky](https://app.hubspot.com/settings/avatar/e26cded5b27070d11a0773d57b23afd4) By   Pablo Grodnitzky  ·   6 minute read

## **Why 85% of Startups Die at Series A (And How Execution Capital Fixes It)**

### **Introduction: The $100 Billion Question**

85% of Seed-funded companies never raise a Series A.

Read that again.

Despite product-market fit. Despite customer traction. Despite experienced founders and top-tier early investors.

**85% die.**

The conventional wisdom says: "Startups fail because the product didn't work, or the market wasn't big enough, or the founder gave up."

**The data says something different.**

The bottleneck isn't product. It's go-to-market execution between $1M-$10M ARR. And venture capital—despite 60 years of evolution—is still organized for the wrong game.

This is the story of why VCs are still at the casino when they should be running a factory. And why that creates a $100B arbitrage opportunity for LPs who understand the difference.

---

### **Part 1: The Market Shifted. VCs Didn't.**

#### 2010: When Capital Was Scarce

In 2010, the hard part of building a startup was building the product.

AWS was 4 years old. Stripe didn't exist. No-code tools were science fiction. If you wanted to build software, you needed:

- $2M+ in Seed capital just to stand up infrastructure
- 18 months to get to MVP
- Technical co-founders who could code
- VCs who could evaluate technical risk

The bottleneck was: **Can you turn a napkin drawing into working software?**

VCs were organized to answer that question:

- Partner with strong technical backgrounds
- Pattern-match on founder pedigree (Stanford CS, ex-Google)
- Evaluate TAM and market timing
- Bet early, spray across 25 - 35 companies, pray for unicorns

**This model made sense. Capital was the constraint. Expertise was abundant.**

#### **2025: When Capital Is Abundant**

Today, the hard part of building a startup is **not** building the product.

- AWS, GCP, and Azure commoditized infrastructure
- Stripe, Plaid, and Twilio commoditized payments and APIs
- Retool, Webflow, and no-code tools commoditized MVPs
- Anyone can raise a $2M Seed round if they have 10 customers

The bottleneck shifted to: **Can you execute GTM from $1M → $10M ARR?**

Specifically:

- Can you transition from founder-led sales to a repeatable motion?
- Can you hire your first 3-5 enterprise AEs without a playbook?
- Can you implement CRM discipline when the founder is still closing deals in email?
- Can you build pipeline generation when the founder's network is exhausted?

**This is where 85% of companies die.**

Yet venture capital is still organized for 2010:

- GPs from finance, strategy, and engineering (not sales)
- 25-35 portfolio companies (no capacity for operational depth)
- Operating Partners from $10B companies (never built a playbook at $2M ARR)
- 10-year lockups betting on unicorns

**Capital is everywhere. Execution infrastructure is rare.**

And VCs haven't adapted.

---

### **Part 2: Why Even Tier 1 VCs Can't Fix This**

"But Sequoia has Operating Partners! They help with GTM!"

Let's examine that claim.

#### **The Operating Partner Résumé**

**Last Role:** EVP Sales at Salesforce  
**Team Managed:** 500 reps, 50 sales managers, full RevOps stack  
**Revenue Responsibility:** $10B+ annually  
**Infrastructure Available:** Demand gen team, sales enablement, partner ecosystem, professional services, customer success org

**What They've Never Done:**

- Built a sales playbook for a 40-person, $2M ARR company
- Hired the first 3 AEs when there's no comp plan, no territories, no defined ICP
- Implemented Salesforce hygiene when the founder closes deals in Gmail
- Run weekly pipeline reviews when there's no pipeline to review
- Transitioned a company from founder-led sales to institutional GTM

#### **The Gap**

Operating Partners can tell you what worked at Oracle.  
They can introduce you to enterprise buyers.  
They can sit on your board and provide strategic guidance.

**They cannot manufacture a repeatable sales motion from scratch.**

Because they've never done it.

They joined Salesforce when it was doing $500M in ARR with 200 reps already in place. They scaled an existing machine. They didn't build it from a 40-person company with a founder selling on personal relationships.

**This is not their fault. It's a structural issue.**

Most VCs come from Strategy, Finance, or Engineering.  
Their Operating Partners come from Fortune 500 scale.  
Neither has experience in the Series A Death Valley: $2M → $15M ARR.

They coach from the boardroom.  
**We execute on the field.**

---

### **Part 3: Casino vs. Factory—Two Models, Two Outcomes**

There are two ways to invest in startups.

#### **The Casino Model (Traditional VC)**

**How it works:**

1. Raise a $150M fund from LPs
2. Charge 2% annual management fees ($3M/year guaranteed)
3. Spray capital across 25-35 companies
4. Hope 1-2 become unicorns (100x returns)
5. Accept 75% will die or return <1x
6. Hold for 10 years, exit via IPO or M&A
7. Return 3-5x to LPs if you picked winners

**Why it's a casino:**

- Success depends on picking outliers (unicorns are ~1% of all tech startups)
- GPs get paid whether companies succeed or fail (2% fees)
- LPs locked in for 10 years with no control or exit optionality
- 75% failure rate is accepted as "the cost of doing business"

**When it made sense:**

- 1970s-2010s: Picking winners early was the alpha
- Capital was scarce, product risk was high
- The hard part was identifying which napkin drawing would become Google

**Why it doesn't work in 2025:**

- Capital is abundant (picking winners doesn't create edge)
- Product risk is low (AWS, Stripe, no-code made building easy)
- The bottleneck is GTM execution (which VCs can't manufacture)

---

#### **The Factory Model (Execution Capital)**

**How it works:**

1. Deploy deal-by-deal SPVs ($2-25M per company)
2. Charge 0% management fees (earn only on performance)
3. Concentrate capital in 3-5 companies per year
4. Embed operators for 90-180 days to manufacture repeatability
5. Target 2.5-4x MOIC on good businesses (not 100x on outliers)
6. Exit at Series B in 3-5 years (not 10-year lockup)
7. Return capital to LPs quickly for next vintage (compounding)

**Why it's a factory:**

- Success depends on manufacturing operational improvements (controllable)
- GPs earn only when LPs win (100% alignment)
- LPs choose each deal with full transparency and exit optionality
- Concentrated portfolio allows operational intensity

**The insight:**

> "We don't need unicorns because we manufacture 3x outcomes on good businesses. Traditional VCs need 100x outcomes because they're locked in for 10 years with 30 companies. We target 3x because we exit fast and compound through multiple vintages."

---

### **Part 4: Growth PE at Series A Pricing (The Arbitrage)**

Growth PE firms have quietly outperformed VC for 20 years.

Here's their playbook:

#### **Traditional Growth PE Model**

1. **Buy:** Companies at $20-50M ARR (8-12x revenue multiples)
2. **Embed:** Operators (CFO, CRO, CMO) to professionalize operations
3. **Drive:** $50M → $100M ARR over 3-5 years
4. **Sell:** At 15-20x revenue to strategics or take public
5. **Return:** 2.5-4x MOIC to LPs in 3-5 years

**Why it works:**

- Not betting on outliers—manufacturing operational improvements
- Concentrated portfolios (5-10 companies) allow deep engagement
- Exit on performance re-rating, not unicorn speculation

**The constraint:** They won't invest below $20M ARR (too small, too risky, too early).

---

#### **PUCP's Arbitrage: Same Playbook, 3 Years Earlier**

1. **Buy:** Companies at $2-5M ARR (5-10x revenue multiples) ⬅️ **3 years earlier, 1/3 the price**
2. **Embed:** Fractional CRO/CMO/CCOs from operator bench to build repeatable GTM
3. **Drive:** $2M → $10M ARR over 18-24 months
4. **Sell:** At Series B (15-25x revenue) to Sequoia, a16z, or growth VCs
5. **Return:** 2.5-4x MOIC to LPs in 3-5 years ⬅️ **Same returns, same timeline**

**Why the gap exists:**

- **Traditional VCs can't do this:** No operational muscle, 30-company portfolios, wrong incentives
- **Growth PE won't do this:** $2M ARR is "too early," no institutional GTM proven
- **Early GTM funds can't do this:** Check sizes too small ($500K can't lead Series A)

**The $2M → $10M ARR gap is structurally mispriced.**

Companies die here not because the product failed—but because:

- Founder-led sales plateaus
- First VP Sales hire underperforms
- No one can build a repeatable motion from scratch
- Traditional VCs pass because "growth is too slow"

**We invest because GTM is fixable.**

Then we manufacture the Series B re-rating.

---

### **Part 5: What Execution Capital Actually Looks Like**

**18-24 Month Value Creation Arc:**

#### **Month 0-1: Diagnose**

- Evaluate PMF (do customers renew, expand, refer?)
- Validate forecast integrity (can founder articulate pipeline math?)
- Audit GTM (is there a playbook, or just founder-sold deals?)
- **Decision:** Walk or proceed

#### **Month 1-3: Design**

- Build sales playbook (discovery, demo, POC, close)
- Design comp plans and territory structure
- Implement RevOps (CRM hygiene, forecasting discipline, metrics tracking)
- Hire sales ops to support reps

#### **Month 3-6: Deploy**

- Embed fractional CRO from operator bench (90-180 days, compensated via 3% Specialist Stake + consulting fees)
- Hire first 2-5 enterprise AEs (sourced from competitive SaaS companies)
- Close first strategic deals to prove motion
- Build pipeline generation engine (outbound + inbound)

#### **Month 6-18: Drive**

- Weekly pipeline reviews (deal progression, forecast accuracy, win/loss analysis)
- Board-level engagement (revenue velocity, CAC payback, sales efficiency)
- Hire VP Sales once motion is proven
- Scale to 5-8 reps with institutional quota attainment

#### **Month 18-24: De-risk**

- Prepare for Series B (institutional metrics, proven GTM, repeatable motion)
- Introduce to institutional VCs (Sequoia, a16z, Lightspeed)
- Facilitate Series B raise at 15-25x revenue multiples
- Exit at valuation re-rating

**Result:**  
$2M ARR → $10M ARR  
Founder-led sales → Institutional GTM  
2.5-4x MOIC in 3-5 years

**No unicorn required.**

---

### **Part 6: The LP Proposition**

Traditional LPs are trapped in a broken model:

**Traditional VC Fund:**

- "Give me $10M for 10 years"
- 2% annual fees ($2M to fees over life of fund)
- Spray across 25 - 35 companies
- Quarterly PowerPoint updates
- No control, no transparency, no exit optionality
- Pray the GP picks a unicorn

**PUCP SPV:**

- "Give me $100K-$5M per deal"
- 0% management fees (earn only when you win)
- 3-5 concentrated investments per year
- Full CRM access, weekly pipeline visibility
- Deal-by-deal transparency and exit optionality
- Underwrite execution risk (controllable), not unicorn speculation

**The Compounding Advantage:**

Traditional VC locks capital for 10 years:

- $10M deployed → locked until Year 10 → $30M returned (3.0x) → 11.6% IRR

PUCP recycles capital every 3-5 years:

- $10M deployed → $27M returned Year 4 (2.7x) → redeploy $27M → $73M returned Year 8 → $130M+ by Year 10 → 35%+ IRR

**Same LP capital. 4-5x more total return through velocity.**

---

### **Conclusion: Execution Is the New Alpha**

The venture capital model was built for a world where:

- Capital was scarce
- Product was hard to build
- Picking winners early was the edge

That world no longer exists.

In 2025:

- Capital is abundant
- Product is easy to build
- The bottleneck is GTM execution from $1M → $10M ARR

Yet VCs are still at the casino, betting on napkins, hoping for unicorns.

**We built a firm for the new game:**

- Concentrated SPVs (3-5 per year)
- Embedded operators (fractional CROs who execute, not advise)
- Fundless structure (0% fees, 100% alignment)
- 3-5 year exits (capital velocity, not 10-year lockups)

**We don't find unicorns. We manufacture repeatability.**

This is execution capital.

---

**Plus Ultra Capital Partners**  
Beyond Expectations

For LPs: [lp.plusultra.capital](https://lp.plusultra.capital/execution-capital)  
For Founders: [info@plusultra.capital](mailto:info@plusultra.capital)

Current Focus: Post-PMF B2B SaaS companies ($1-5M ARR) with proven product, strong retention, and fixable GTM.

 Contact Us

Share: [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://lp.plusultra.capital/insights/the-venture-capital-paradox-why-85-of-startups-die-at-series-a-and-how-execution-capital-fixes-it) [envelope icon](mailto:?body=https://lp.plusultra.capital/insights/the-venture-capital-paradox-why-85-of-startups-die-at-series-a-and-how-execution-capital-fixes-it) [Share this page on Facebook](https://twitter.com/intent/tweet?url=https://lp.plusultra.capital/insights/the-venture-capital-paradox-why-85-of-startups-die-at-series-a-and-how-execution-capital-fixes-it)

Copyright © 2026, Plus Ultra Capital Partners

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Pablo Grodnitzky",
    "url" : "https://lp.plusultra.capital/insights/author/pablo-grodnitzky"
  },
  "dateModified" : "2025-10-24T00:55:52.461Z",
  "datePublished" : "2025-10-16T23:26:17.000Z",
  "headline" : "The Venture Capital Paradox",
  "image" : [ "https://lp.plusultra.capital/hubfs/Logos/Blu%20Sqr%20Satoshi%20PUC%20stacked%20lrg.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://lp.plusultra.capital/insights/the-venture-capital-paradox-why-85-of-startups-die-at-series-a-and-how-execution-capital-fixes-it",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://lp.plusultra.capital/hubfs/Blu%20Sqr%20Satoshi%20PUC%20stack%20lrg%20let%20sm.png"
    },
    "name" : "Plus Ultra Capital Partners"
  }
}
```

```json
{
  "@context" : "http://schema.org",
  "@type" : "Article",
  "author" : {
    "@type" : "Person",
    "name" : [ "Pablo Grodnitzky" ]
  },
  "datePublished" : "2025-10-16T23:26:17+0000",
  "description" : "venture capital, Series A funding, GTM execution, go-to-market strategy, startup death valley, execution capital, fundless SPV, LP returns",
  "headline" : "The Venture Capital Paradox",
  "image" : "https://6431287.fs1.hubspotusercontent-na2.net/hubfs/6431287/Logos/Blu%20Sqr%20Satoshi%20PUC%20stacked%20lrg.png",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://6431287.fs1.hubspotusercontent-na2.net/hubfs/6431287/Blu%20Sqr%20Satoshi%20PUC%20stack%20lrg%20let%20sm.png"
    },
    "name" : "Plus Ultra Capital Partners"
  },
  "url" : "https://lp.plusultra.capital/insights/the-venture-capital-paradox-why-85-of-startups-die-at-series-a-and-how-execution-capital-fixes-it"
}
```